GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Total Stockholders Equity

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Total Stockholders Equity : ¥6,987 Mil (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Total Stockholders Equity?

Tianjin Pharmaceutical Da Ren Tang Group's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥6,987 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Tianjin Pharmaceutical Da Ren Tang Group's Book Value per Share for the quarter that ended in Mar. 2024 was ¥9.07. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Tianjin Pharmaceutical Da Ren Tang Group's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.09.


Tianjin Pharmaceutical Da Ren Tang Group Total Stockholders Equity Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Total Stockholders Equity Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,388.17 5,808.41 6,364.48 6,521.46 6,600.69

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,905.22 6,332.32 6,468.06 6,600.69 6,987.13

Tianjin Pharmaceutical Da Ren Tang Group  (SHSE:600329) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Tianjin Pharmaceutical Da Ren Tang Group's Book Value per Share for the quarter that ended in Mar. 2024 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Tianjin Pharmaceutical Da Ren Tang Group's Debt-to-Equity for the quarter that ended in Mar. 2024 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Pharmaceutical Da Ren Tang Group Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines

No Headlines